Terra Nova Asset Management LLC Has $1.76 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Terra Nova Asset Management LLC decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,321 shares of the medical research company’s stock after selling 567 shares during the quarter. Terra Nova Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $1,763,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Halpern Financial Inc. raised its position in shares of Thermo Fisher Scientific by 307.7% during the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after acquiring an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $33,000. Live Oak Investment Partners bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $36,000. Tyler Stone Wealth Management acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth $38,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Robert W. Baird reissued an “outperform” rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective for the company. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $599.00.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $581.21 on Friday. The stock’s fifty day moving average price is $565.13 and its two-hundred day moving average price is $520.22. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The firm has a market cap of $221.62 billion, a PE ratio of 37.62, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter last year, the company posted $5.40 EPS. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 in the last 90 days. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.